Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
In a well-insured cohort of older people with HIV, antiretroviral treatment didn’t offset the risk for dementia.
Sudden cognitive dysfunction is a common concern for seniors who’ve survived a serious bout of COVID-19.
While people with HIV have a higher rate of early Alzheimer’s than those without the virus, treatment appears to eliminate this excess risk.
A recent study of veterans found that antiretroviral treatment was not associated with a mitigated dementia risk.
A $7 million grant goes to new research seeking insights to neurological and cognitive problems.
HIV leads to brain inflammation and cognitive decline, but adding marijuana to the mix doesn’t seem to further such damage.
Factors associated with a higher risk of impairment include depression, poor adherence to antiretrovirals and opportunistic infections.
A study suggests cannabis use is linked to lower odds of neurocognitive problems in this population.
That’s the core message of an essay by Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases.
After almost a decade on antiretroviral therapy, half of study participants still had HIV in immune cells in their brain and spinal fluid.
HIV-related stigma is reported to have harsh effects on cognition.
That’s compared with a control group of HIV-negative individuals in a small study.
A research team has sought to address the critical lack of treatment guidelines for addressing HIV’s complex effects on aging.
Such effects have a downstream impact on the real-world functioning of people with HIV.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.